ATXN3 and neuroblastoma: Mutant protein knockdown by LNA8-17Dz9 is best achieved in neuronal cells (iNeuron and neuroblastoma, > 90%), followed by kidney embryonic cells (HEK293, 80–100%), patient-derived fibroblasts (SCA1 and SCA3, 40–60%), and patient-derived iPSCs (SCA3, 50%).